Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Done. Not a doctor or a scientist, but I posted:

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155513
(Total Views: 954)
Posted On: 08/16/2020 7:11:10 PM
Posted By: CTMedic
Re: invisioner #49956
Done. Not a doctor or a scientist, but I posted:

The pathogenicity of Covid, as in Ebola, is due to an overwhelming and disproportionate immune response, which results in the “cytokine storm”. The success in Britain of dexamethasone in severe
patients demonstrated that reducing immune over reaction can save lives. Target monoclonal antibodies will be a much more effective therapeutic, much less of the blunt tool, but moderately successful tool
of corticosteroids

Humanigen’s lenzilumab is promising, as it blocks GM-CSF stopping, the proliferation and differentiation of stem cells into macrophages, neutrophils, basophils, dendritic cells, and eosinophils.

Even more promising is leronlimab, which is a receptor site antibody of CCR5. Blocking CCR5 stops the trafficking of existing populations of the same macrophages, basophils, neutrophils and eosinophils to areas of inflammation, reversing the cytokine storm.

Additionally, leronlimab repolarizes macrophages to an anti inflammatory state and reverses exhaustion of CD8 T cells, so that they resume normal function, which includes production of granzyme-A, which lyses virally infected cells and eliminates viremia.

So no, none of these therapeutics block viral entry. TMPRSS2 blockers may at some point. However, as another poster noted, leronlimab has demonstrated efficacy in treating the immune dysregulation of Covid 19. In a phase 2 study, with P=0.02. Severe adverse events and progression to severe disease
were both markedly reduced.
We can wait years for RNA transcriptase inhibitors and TMPR22 blockers, or we can use leronlimab now, saving millions of lives and hundreds of billions of dollars.


(15)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us